These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1565 related items for PubMed ID: 28270207

  • 1. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May 08; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015 May 08; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May 08; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
    Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW.
    Clin Ther; 2016 Mar 08; 38(3):655-67.e1-2. PubMed ID: 26907504
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ.
    BMC Health Serv Res; 2017 Jan 26; 17(1):87. PubMed ID: 28122562
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
    Byun JH, Park JA, Kang HR, Shin JY, Lee EK.
    Clin Drug Investig; 2016 Nov 26; 36(11):957-968. PubMed ID: 27465204
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bedaquiline and delamanid in tuberculosis.
    Esposito S, Bianchini S, Blasi F.
    Expert Opin Pharmacother; 2015 Nov 26; 16(15):2319-30. PubMed ID: 26293803
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
    Zwerling A, Dowdy D, von Delft A, Taylor H, Merritt MW.
    Int J Tuberc Lung Dis; 2017 Nov 01; 21(11):69-74. PubMed ID: 29025487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.